Cent Eur J Public Health 2009, 17(4):191-197 | DOI: 10.21101/cejph.a3562

Select Barriers to Harm-reduction Services for IDUs in Eastern Europe

Nadja Kehler Curth1, Liv Nanna Hansson1, Frederikke Storm1, Jeffrey V. Lazarus1,2
1 Department of Public Health, Copenhagen University, Denmark
2 Copenhagen School of Global Health, Copenhagen University, Denmark

Background: In eastern Europe, the high prevalence rates of HIV and the hepatitis C virus (HCV) are concentrated among injecting drug users (IDUs). Harm reduction programmes such as needle and syringe programmes and opioid substitution therapy (OST) have been shown to be effective in preventing these infections. However, structural barriers can limit their effectiveness by hindering access.

Methods: Through use of a semi-structured online survey sent to 65 professionals in the region, this study explores the prevalences of age restrictions, user fees or a lack of confidentiality for these programmes as well as HIV/HCV testing programmes.

Results: Twenty respondents reported that age restrictions were not widespread in the 11 reporting countries, apart from for OST. User fees were found to be very common in HCV testing and varied for other services. It was stated to be common to inform parents of young IDUs who receive HIV services, but not to inform public authorities when IDUs enter harm reduction programmes.

Conclusion: Where access to services is limited or confidentiality is compromised, as reported in this pilot study, it is crucial that health-care guidelines and national legislation are reformed to ensure access to these evidence-based interventions.

Keywords: harm reduction, health policy, hepatitis, HIV, eastern Europe, central Asia

Received: May 5, 2009; Revised: June 23, 2009; Accepted: June 23, 2009; Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kehler Curth N, Hansson LN, Storm F, Lazarus JV. Select Barriers to Harm-reduction Services for IDUs in Eastern Europe. Cent Eur J Public Health. 2009;17(4):191-197. doi: 10.21101/cejph.a3562. PubMed PMID: 20377047.
Download citation

References

  1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2001 AIDS epidemic update: Eastern Europe and Central Asia. Geneva: UNAIDS; 2001.
  2. Reversing the tide: priorities for HIV/AIDS prevention in Central Asia. Washington, DC: World Bank; 2005.
  3. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2007AIDS epidemic update: Eastern Europe and Central Asia. Geneva: UNAIDS; 2007.
  4. Joint United Nations Programme on HIV/AIDS; World Health Organization (WHO). Progress on implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia. Copenhagen: WHO Regional Office for Europe; 2008.
  5. Knerr W, Merkinaite S, editors. Hepatitis C among injecting drug users in the new EU member states and neighboring countries: situation, guidelines and recommendations. Vilnius: Central and Eastern European Harm Reduction Network; 2007.
  6. Michielsen P, Bottieau E. Therapy of chronic hepatitis C in the setting of HIV co-infection. Acta Gastroenterol Belg. 2005 Jan-Mar;68(1):86-91. Go to PubMed...
  7. Schwalbe N, Lazarus JV, Adeyi O. HIV/AIDS and tuberculosis control in post-soviet countries. In: McKee M, Coker R, Atun RA, editors. Communicable diseases in Europe. Buckingham: Open University Press; 2008.
  8. Elovich R, Drucker E. On drug treatment and social control: Russian narcology's great leap backwards. Harm Reduct J. 2008 Jun 24;5:23. Go to original source... Go to PubMed...
  9. Donoghoe MC, Lazarus JV, Matic S. HIV/AIDS in the transitional countries of Eastern Europe and Central Asia. Clin Med. 2005 SepOct;5(5):487-90. Go to original source...
  10. Lazarus JV, Shete PB, Eramova I, Merkinaite S, Matic S. HIV/hepatitis coinfection in eastern Europe, and new pan-European approaches to hepatitis prevention and management. Int J Drug Policy. 2007 Oct;18(5):42632. Go to original source... Go to PubMed...
  11. Donoghoe MC. Injecting drug use, harm reduction and HIV/AIDS. In: Matic S, Lazarus JV, Donoghoe MC, editors. HIV/AIDS in Europe: moving from death sentence to chronic disease management. Copenhagen: WHO Regional Office for Europe; 2006.
  12. World Health Organization [homepage on the Internet]. Evidence for action technical paper: effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. 2004 [cited 2008 May 13]. Available from: www.who.int/hiv/pub/prev_care/en/effectivenesssterileneedle.pdf.
  13. Gowing L, Farrell M, Bornemann R, Sullivan L,Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008 Apr 16;2(2):CD004145. Go to original source... Go to PubMed...
  14. World Health Organization [homepage on the Internet]. Evidence for action technical paper: effectiveness of drug dependence treatment in preventing HIV among injecting drug users. 2005 [cited 2008 May 17]. Available from: http://www.who.int/hiv/pub/idu/drugdependence_final.pdf.
  15. Deren S, Beardsley M, Coyle S, Singer M. HIV serostatus and risk behaviors in a multisite sample of drug users. J Psychoactive Drugs. 1998 Jul-Sep;30(3):239-45. Go to original source... Go to PubMed...
  16. Des Jarlais DC, Friedman SR. Critical issues regarding AIDS among injecting drug users. Bull Narc. 1993;45(1):61-75. Go to PubMed...
  17. Harm Reduction Coalition [homepage on the Internet]. Principles of harm reduction [cited 2008 Jan 26].Available from: http://www.harmreduction.org/article.php?list=type&type=62.
  18. Open Society Institute [homepage on the Internet]. Harm reduction: questions and answers [cited 2008 Jan 26]. Available from: http://www.soros.org/initiatives/health/focus/ihrd/articles_publications/publications/qa_20041123/harm_qa_english.pdf.
  19. Atun RA. How European health systems have reacted to the HIV/AIDS epidemic. In: Matic S, Lazarus JV, Donoghoe MC, editors. HIV/AIDS in Europe: moving from death sentence to chronic disease management. Copenhagen: WHO Regional Office for Europe; 2006.
  20. European Commission [homepage on the Internet]. Dublin Declaration on Partnership to fight HIV/AIDS in Europe and Central Asia. 2004 [cited 2008 May 12]. Available from: http://ec.europa.eu/health/ph_threats/com/aids/docs/dublin_decl.pdf.
  21. Grund J-P, Merkinaite S, editors. Young people & injecting drug use in selected countries of Central and Eastern Europe. Vilnius: Eurasian Harm Reduction Network; 2009.
  22. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2007. Stockholm: European Centre for Disease Prevention and Control; 2008.
  23. European Monitoring Centre for Drugs and Drug Addiction [homepage on the Internet]. Statistical bulletin 2008 [cited 2008 May 12]. Available from: http://www.emcdda.europa.eu/stats08.
  24. Mossialos E, DixonA, Figueras J, Kutzin J, editors. Funding health care: options for Europe. Buckingham: Open University Press; 2002.
  25. McCoy CB, Metsch LR, Chitwood DD, Miles C. Drug use and barriers to use of health care services. Subst Use Misuse 2001 May-Jun;36(67):789-806. Go to original source...
  26. Bobrova N, Rhodes T, Power R,Alcorn R, Neifeld E, Krasiukov N, et al. Barriers to accessing drug treatment in Russia: a qualitative study among injecting drug users in two cities. Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S57-63. Go to original source...
  27. Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-monoinfected and HIV/HCV-co-infected injection drug users. AIDS. 2005 Oct;19 Suppl 3:S179-89. Go to original source... Go to PubMed...
  28. Copeland J. A qualitative study of barriers to formal treatment among women who self-managed change in addictive behaviours. J SubstAbuse Treat. 1997 Mar-Apr;14(2):183-90. Go to original source...
  29. Booth RE, Kwiatkowski C, Iguchi MY, Pinto F, John D. Facilitating treatment entry among out-of-treatment injection drug users. Public Health Rep. 1998 Jun;113 Suppl 1:116-28.
  30. Cronquist A, Edwards V, Galea S, Latka M, Vlahov D. Health care utilization among young adult injection drug users in Harlem, New York. J Subst Abuse. 2001;13(1-2):17-27. Go to original source...
  31. Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy. 2007 Aug;18(4):246-54. Go to original source... Go to PubMed...
  32. Maher L, Coupland H, Musson R. Scaling up HIV treatment, care and support for injecting drug users in Vietnam. Int J Drug Policy. 2007 Aug;18(4):296-305. Go to original source... Go to PubMed...
  33. Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine-programme description and policy implications. Int J Drug Policy. 2007 Aug;18(4):326-28. Go to original source... Go to PubMed...
  34. UNAIDS [homepage on the Internet]. The Paris Declaration. 1994 [cited 2008 May 12].Available from: http://data.unaids.org/pub/ExternalDocument/2007/theparisdeclaration_en.pdf.
  35. World HepatitisAlliance [homepage on the Internet]. World hepatitis day [cited 2008 Sep 23]. Available from: http://www.aminumber12.org/.
  36. World Health Organization [homepage on the Internet]. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs) [cited 2009Apr 7].Available from: http://www.who.int/hiv/pub/idu/targetsetting/en/index.html.
  37. Blystad H, Wiessing L. Guidance on provider-initiated voluntary medical examination: testing and counselling for infectious diseases in injecting drug users. Pre-final unedited version 4.5. Lisbon: EMCDDA; 2009.
  38. White CL. Beyond professional harm reduction: the empowerment of multiply-marginalized illicit drug users to engage in a politics of solidarity towards ending the war on illicit drug users. Drug Alcohol Rev. 2001;20(4):449-58. Go to original source...